<< Read Full Article
<< Read Full Article
Genzyme Misses Product-Sales Estimates
- Loading Comments...
Genzyme(GENZ Quote) beat analysts' earnings estimates in the latest quarter, but it missed Wall Street's sales targets for its key products, and shares eased Wednesday.
The company reported a third-quarter profit of $119.6 million, or 42 cents a share, down from $159.3 million, or 58 cents a share, in the year-ago quarter. The recent quarter included a $100 million licensing fee for the rights to a late-stage genetic disease drug developed by PTC Therapeutics.
On an adjusted basis, the company said it earned $1.04 a share, up from 90 cents last year, on revenue that rose 20% to $1.16 billion. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,406.89 | 1,103.06 | 2,197.58 | 34.87 |
Oil *
71.59
|
|
UP
69.84
|
UP
7.12
|
UP
13.85
|
UP
0.64
|
10 Yr
3.49%
SPDR Gold
110.56
|
|
+0.68%
|
+0.65%
|
+0.63%
|
+1.87%
|
Data delayed 20 minutes |


Connect with TheStreet